{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T20:13:57Z","timestamp":1791231237937,"version":"4.1.0"},"reference-count":45,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,5]]},"DOI":"10.1097\/cji.0b013e31816dad10","type":"journal-article","created":{"date-parts":[[2008,4,21]],"date-time":"2008-04-21T03:03:00Z","timestamp":1208746980000},"page":"420-430","source":"Crossref","is-referenced-by-count":96,"title":["A Multipeptide Vaccine is Safe and Elicits T-cell Responses in Participants With Advanced Stage Ovarian Cancer"],"prefix":"10.1097","volume":"31","author":[{"given":"Kimberly A.","family":"Chianese-Bullock","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William P.","family":"Irvin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gina R.","family":"Petroni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheryl","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Smolkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter C.","family":"Olson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Coleman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott A.","family":"Boerner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmel J.","family":"Nail","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrice Y.","family":"Neese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arlene","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin T.","family":"Hogan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig L.","family":"Slingluff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-11-20210219","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3322\/canjclin.57.1.43","article-title":"Cancer statistics, 2007","volume":"57","author":"Jemal","year":"2007","journal-title":"CA Cancer J Clin"},{"key":"R2-11-20210219","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s002620050559","article-title":"Study of HLA class I restriction and the directed antigens of cytotoxic T lymphocytes at the tumor sites of ovarian cancer","volume":"48","author":"Yamada","year":"1999","journal-title":"Cancer Immunol Immunother"},{"key":"R3-11-20210219","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1002\/(SICI)1097-0215(19970926)73:1<143::AID-IJC22>3.0.CO;2-G","article-title":"Generation and phenotypic characterization of new human ovarian cancer cell lines with the identification of antigens potentially recognizable by HLA-restricted cytotoxic T cells","volume":"73","author":"Ramakrishna","year":"1997","journal-title":"Int J Cancer"},{"key":"R4-11-20210219","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1006\/gyno.1996.0075","article-title":"Effects of irradiation on the expression of surface antigens in human ovarian cancer","volume":"60","author":"Santin","year":"1996","journal-title":"Gynecol Oncol"},{"key":"R5-11-20210219","first-page":"557","article-title":"Trophoblast and ovarian cancer antigen LK26. Sensitivity and specificity in immunopathology and molecular identification as a folate binding protein","volume":"142","author":"Garin-Chesea","year":"1993","journal-title":"Am J Pathol"},{"key":"R6-11-20210219","first-page":"665","article-title":"Local concentration of folate binding protein GP38 in sections of human ovarian carcinoma by in vitro quantitative autoradiography","volume":"37","author":"Li","year":"1996","journal-title":"J Nucl Med"},{"key":"R7-11-20210219","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1126\/science.2470152","article-title":"Studies of the HER-2\/neu proto-oncogene in human breast and ovarian cancer","volume":"244","author":"Slamon","year":"1989","journal-title":"Science"},{"key":"R8-11-20210219","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1038\/bjc.1998.585","article-title":"MAGE, BAGE and GAGE: tumour antigen expression in benign and malignant ovarian tissue","volume":"78","author":"Gillespie","year":"1998","journal-title":"Br J Cancer"},{"key":"R9-11-20210219","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa020177","article-title":"Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer","volume":"348","author":"Zhang","year":"2003","journal-title":"N Engl J Med"},{"key":"R10-11-20210219","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/nm0398-321","article-title":"Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma","volume":"4","author":"Rosenberg","year":"1998","journal-title":"Nat Med"},{"key":"R11-11-20210219","doi-asserted-by":"crossref","first-page":"4016","DOI":"10.1200\/JCO.2003.10.005","article-title":"Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells","volume":"21","author":"Slingluff","year":"2003","journal-title":"J Clin Oncol"},{"key":"R12-11-20210219","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1002\/ijc.2910390306","article-title":"Characterization of human ovarian carcinoma-associated antigens defined by novel monoclonal antibodies with tumor-restricted specificity","volume":"39","author":"Miotti","year":"1987","journal-title":"Int J Cancer"},{"key":"R13-11-20210219","first-page":"4087","article-title":"Overexpression of HER-2\/neu is associated with poor survival in advanced epithelial ovarian cancer","volume":"50","author":"Berchuck","year":"1990","journal-title":"Cancer Res"},{"key":"R14-11-20210219","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0090-8258(03)00065-9","article-title":"Her-2\/neu expression in ovarian cancer: pre- and postexposure to platinum chemotherapy","volume":"89","author":"Peethambaram","year":"2003","journal-title":"Gynecol Oncol"},{"key":"R15-11-20210219","first-page":"2479","article-title":"Enhancement of cytolytic T lymphocyte precursor frequency in melanoma patients following immunization with the MAGE-1 peptide loaded antigen presenting cell-based vaccine","volume":"56","author":"Hu","year":"1996","journal-title":"Cancer Res"},{"key":"R16-11-20210219","doi-asserted-by":"crossref","first-page":"8078","DOI":"10.1073\/pnas.92.17.8078","article-title":"Induction of antigen-specific cytolytic T cells in situ in human melanoma by immunization with synthetic peptide-pulsed autologous antigen presenting cells","volume":"92","author":"Mukherji","year":"1995","journal-title":"Proc Natl Acad Sci USA"},{"key":"R17-11-20210219","doi-asserted-by":"crossref","first-page":"6386","DOI":"10.1158\/1078-0432.CCR-07-0486","article-title":"Immunologic and clinical outcomes of a randomized phase II trial of two multipeptide vaccines for melanoma in the adjuvant setting","volume":"13","author":"Slingluff","year":"2007","journal-title":"Clin Cancer Res"},{"key":"R18-11-20210219","doi-asserted-by":"crossref","first-page":"3102","DOI":"10.1182\/blood.V96.9.3102","article-title":"Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells","volume":"96","author":"Brossart","year":"2000","journal-title":"Blood"},{"key":"R19-11-20210219","first-page":"431","article-title":"Identification of HLA-A3\u2013restricted cytotoxic T lymphocyte epitopes from carcinoembryonic antigen and HER-2\/neu by primary in vitro immunization with peptide-pulsed dendritic cells","volume":"59","author":"Kawashima","year":"1999","journal-title":"Cancer Res"},{"key":"R20-11-20210219","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1007\/BF02303486","article-title":"Ovarian cancer-associated lymphocyte recognition of folate binding protein peptides","volume":"5","author":"Peoples","year":"1998","journal-title":"Ann Surg Oncol"},{"key":"R21-11-20210219","first-page":"4214","article-title":"Vaccine implications of folate binding protein, a novel cytotoxic T lymphocyte-recognized antigen system in epithelial cancers","volume":"5","author":"Peoples","year":"1999","journal-title":"Clin Cancer Res"},{"key":"R22-11-20210219","first-page":"2907","article-title":"Folate binding protein peptide 191-199 presented on dendritic cells can stimulate CTL from ovarian and breast cancer patients","volume":"19","author":"Kim","year":"1999","journal-title":"Anticancer Res"},{"key":"R23-11-20210219","first-page":"2251","article-title":"Clarification of the functional significance of human folate-binding protein-alpha, peptide 191-199, based on a correct GenBank sequence and on other FBP (191-199) sequences","volume":"27","author":"Ioannides","year":"2007","journal-title":"Anticancer Res"},{"key":"R24-11-20210219","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1084\/jem.20041270","article-title":"Loss of HIV-1-specific CD8+ T cell proliferation after acute HIV-1 infection and restoration by vaccine-induced HIV-1-specific CD4+ T cells","volume":"200","author":"Lichterfeld","year":"2004","journal-title":"J Exp Med"},{"key":"R25-11-20210219","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1007\/s00262-004-0653-2","article-title":"Tumor antigen-specific T helper cells in cancer immunity and immunotherapy","volume":"54","author":"Knutson","year":"2005","journal-title":"Cancer Immunol Immunother"},{"key":"R26-11-20210219","first-page":"3012","article-title":"Phase I trial of a melanoma vaccine with gp100 (280-288) peptide and tetanus helper peptide in adjuvant: immunologic and clinical outcomes","volume":"7","author":"Slingluff","year":"2001","journal-title":"Clin Cancer Res"},{"key":"R27-11-20210219","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/S0065-2776(06)90007-8","article-title":"Immunity to melanoma antigens: from self-tolerance to immunotherapy","volume":"90","author":"Slingluff","year":"2006","journal-title":"Adv Immunol"},{"key":"R28-11-20210219","doi-asserted-by":"crossref","first-page":"394","DOI":"10.4049\/jimmunol.142.2.394","article-title":"Delineation of several DR-restricted tetanus toxin T cell epitopes","volume":"142","author":"Demotz","year":"1989","journal-title":"J Immunol"},{"key":"R29-11-20210219","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.4049\/jimmunol.147.5.1512","article-title":"HIV-1 gag-specific cytotoxic T lymphocytes recognize multiple highly conserved epitopes. Fine specificity of the gag-specific response defined by using unstimulated peripheral blood mononuclear cells and cloned effector cells","volume":"147","author":"Johnson","year":"1991","journal-title":"J Immunol"},{"key":"R30-11-20210219","doi-asserted-by":"crossref","first-page":"3080","DOI":"10.4049\/jimmunol.174.5.3080","article-title":"MAGE-A1, MAGE-A10, and gp100 derived peptides are immunogenic when combined with GM-CSF and montanide ISA-51 adjuvant and administered as part of a multi-peptide vaccine for melanoma","volume":"174","author":"Chianese-Bullock","year":"2005","journal-title":"J Immunol"},{"key":"R31-11-20210219","doi-asserted-by":"crossref","DOI":"10.1002\/0471725315","article-title":"Nonlinear Regression","author":"Seber","year":"1989"},{"key":"R33-11-20210219","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/nm0398-328","article-title":"Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells","volume":"4","author":"Nestle","year":"1998","journal-title":"Nat Med"},{"key":"R34-11-20210219","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1023\/A:1021904432489","article-title":"Pilot study of an HLA-A2 peptide vaccine using flt3 ligand as a systemic vaccine adjuvant","volume":"23","author":"McNeel","year":"2003","journal-title":"J Clin Immunol"},{"key":"R35-11-20210219","doi-asserted-by":"crossref","first-page":"4474","DOI":"10.1200\/JCO.2004.10.212","article-title":"Immunologic and clinical outcomes of vaccination with a multiepitope melanoma peptide vaccine plus low-dose interleukin-2 administered either concurrently or on a delayed schedule","volume":"22","author":"Slingluff","year":"2004","journal-title":"J Clin Oncol"},{"key":"R36-11-20210219","first-page":"4766","article-title":"Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer","volume":"61","author":"Woo","year":"2001","journal-title":"Cancer Res"},{"key":"R37-11-20210219","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1054\/bjoc.2001.1847","article-title":"Modulation of TcR\/CD3-zeta chain expression by a circulating factor derived from ovarian cancer patients","volume":"84","author":"Taylor","year":"2001","journal-title":"Br J Cancer"},{"key":"R38-11-20210219","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1016\/j.lfs.2003.07.051","article-title":"Ovarian carcinoma cells inhibit T cell proliferation: suppression of IL-2 receptor beta and gamma expression and their JAK-STAT signaling pathway","volume":"74","author":"Wang","year":"2004","journal-title":"Life Sci"},{"key":"R39-11-20210219","first-page":"399","article-title":"Proportion of CD4+ CD25+ regulatory T cell is increased in the patients with ovarian carcinoma","volume":"23","author":"Li","year":"2005","journal-title":"Cancer Invest"},{"key":"R40-11-20210219","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1081\/CNV-67128","article-title":"Ovarian carcinoma cells effectively inhibit differentiation and maturation of dendritic cells derived from hematopoietic progenitor cells in vitro","volume":"23","author":"Ye","year":"2005","journal-title":"Cancer Invest"},{"key":"R41-11-20210219","doi-asserted-by":"crossref","first-page":"2928","DOI":"10.4049\/jimmunol.163.5.2928","article-title":"Identification of five MAGE-A1 epitopes recognized by cytolytic T lymphocytes obtained by in vitro stimulation with dendritic cells transduced with MAGE-A1","volume":"163","author":"Chaux","year":"1999","journal-title":"J Immunol"},{"key":"R42-11-20210219","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1002\/(SICI)1097-0215(19990827)82:5<669::AID-IJC9>3.0.CO;2-#","article-title":"Mass-spectrometric evaluation of HLA-A*0201-associated peptides identifies dominant naturally processed forms of CTL epitopes from MART-1 and gp100","volume":"82","author":"Skipper","year":"1999","journal-title":"Int J Cancer"},{"key":"R43-11-20210219","first-page":"5850","article-title":"Heterogeneous T-cell response to MAGE-A10(254-262): high avidity-specific cytolytic T lymphocytes show superior antitumor activity","volume":"61","author":"Dutoit","year":"2001","journal-title":"Cancer Res"},{"key":"R44-11-20210219","doi-asserted-by":"crossref","first-page":"989","DOI":"10.4049\/jimmunol.162.2.989","article-title":"High avidity CTLs for two self-antigens demonstrate superior in vitro and in vivo antitumor efficacy","volume":"162","author":"Zeh HJ","year":"1999","journal-title":"J Immunol"},{"key":"R45-11-20210219","doi-asserted-by":"crossref","first-page":"5824","DOI":"10.4049\/jimmunol.167.10.5824","article-title":"Manipulation of avidity to improve effectiveness of adoptively transferred CD8(+) T cells for melanoma immunotherapy in human MHC class I-transgenic mice","volume":"167","author":"Bullock","year":"2001","journal-title":"J Immunol"},{"key":"R46-11-20210219","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1002\/eji.200324427","article-title":"The CD8(+) T cell repertoire against Her-2\/neu antigens in neu transgenic mice is of low avidity with antitumor activity","volume":"34","author":"Lustgarten","year":"2004","journal-title":"Eur J Immunol"}],"container-title":["Journal of Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/CJI.0b013e31816dad10","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T17:08:32Z","timestamp":1786036112000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00002371-200805000-00011"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,5]]},"references-count":45,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2008]]}},"URL":"https:\/\/doi.org\/10.1097\/cji.0b013e31816dad10","relation":{},"ISSN":["1524-9557"],"issn-type":[{"value":"1524-9557","type":"print"}],"subject":[],"published":{"date-parts":[[2008,5]]}}}